N. Perez
University of Paris
5 Papers
35 Citations
N. Perez is an academic researcher from University of Paris. The author has contributed to research in topics: Oxaliplatin & GemOx. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer
Arie Figer,N. Perez,Elisabeth Carola,T. Andre,Isabel Chirivella,Gérard Lledo,M. Flesch,Fernando Rivera,Philippe Colin,A. de Gramont +9 more
TL;DR: This report concerns the tolerance and the efficacy observed for the 37 pts aged 75 years or older in the OPTIMOX trial, which consisted in a phase III study for pts with conventional inclusion criteria and two exploratory studies in pts > 75 yrs and in pts with Alk Ph level > 3-time the UNV.
15
Survie à long terme des cancers colorectaux métastatiques sous chimiothérapie par 5-fluoro-uracile
N. Perez,Christophe Tournigand,May Mabro,JL Molitor,Pascal Artru,Elisabeth Carola,T. Andre,C. Louvet,Marcel Krulik,A. de Gramont +9 more
TL;DR: Cette etude montre que certains patients peuvent avoir une survie prolongee et que 1 % des patients ont pu etre gueris uniquement avec une chimiotherapie a base de 5-fluoro-uracile.
10
EXIBIT: An international multicenter phase II trial of gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer
T. Andre,J. M. Reyes-Vidal,Laetitia Fartoux,Paul Ross,M. Leslie,Olivier Rosmorduc,M. R. Clemens,C. Louvet,N. Perez,Werner Scheithauer +9 more
TL;DR: GEMOX has acceptable toxicity in patients with advanced biliary tract carcinomas and an interim analysis of OS and safety is reported.
7
Docetaxel (D) and oxaliplatin (DOCELOX) in advanced ovarian cancer (AOC): Preliminary safety results of a phase I-II
Christophe Tournigand,Elisabeth Carola,F. Maindrault Goebel,M. Bennamoun,M.L. Garcia,H. Gervais,N. Perez,A. Plantade,C. Louvet,A. de Gramont +9 more
TL;DR: A phase I-II study was initiated to evaluate docetaxel (D) and oxaliplatin in AOC and to evaluate the potential of these drugs in combination with chemotherapy.
4
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study
Thierry André,J. M. Reyes-Vidal,Laetitia Fartoux,Paul Ross,M. Leslie,Olivier Rosmorduc,M. R. Clemens,C. Louvet,N. Perez,F Mehmud,Werner Scheithauer +10 more
TL;DR: In this study, GEMOX demonstrated activity in non-gallbladder carcinoma, but poor activity in gallbladder cancer, and is well tolerated in advanced BTCs.